1
|
Cai H, Zheng R, Wu N, Hu J, Wang R, Chi J, Zhang W, Zhao L, Cheng H, Chen A, Li S, Xu L. Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition. Pharmaceutics 2023; 15:2377. [PMID: 37896137 PMCID: PMC10610039 DOI: 10.3390/pharmaceutics15102377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Revised: 09/03/2023] [Accepted: 09/19/2023] [Indexed: 10/29/2023] Open
Abstract
Chemotherapy-induced side effects restrain anti-tumor efficiency, with hyperlipidemia being the most common accompanying disease to cause treatment failure. In this work, a chimeric peptide-engineered nanomedicine (designated as PRS) was fabricated for the synergistic suppression of tumor growth and therapy-induced hyperlipidemia. Within this nanomedicine, the tumor matrix-targeting peptide palmitic-K(palmitic)CREKA can self-assemble into a nano-micelle to encapsulate Rapamycin (mTOR inhibitor) and SBC-115076 (PCSK9 inhibitor). This PRS nanomedicine exhibits a uniform nano-distribution with good stability which enhances intracellular drug delivery and tumor-targeting delivery. Also, PRS was found to synergistically inhibit tumor cell proliferation by interrupting the mTOR pathway and reducing Rapamycin-induced hyperlipidemia by increasing the production of LDLR. In vitro and in vivo results demonstrate the superiority of PRS for systematic suppression of tumor growth and the reduction of hyperlipidemia without initiating any other toxic side effects. This work proposes a sophisticated strategy to inhibit tumor growth and also provides new insights for cooperative management of chemotherapy-induced side effects.
Collapse
Affiliation(s)
- Hua Cai
- Department of Geriatric Cardiology, General Hospital of Southern Theater Command, People’s Liberation Army, Guangzhou 510010, China; (H.C.); (N.W.); (J.H.); (R.W.); (J.C.)
- Graduate School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China
| | - Rongrong Zheng
- Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China; (R.Z.); (L.Z.)
| | - Ningxia Wu
- Department of Geriatric Cardiology, General Hospital of Southern Theater Command, People’s Liberation Army, Guangzhou 510010, China; (H.C.); (N.W.); (J.H.); (R.W.); (J.C.)
- Graduate School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China
| | - Jiaman Hu
- Department of Geriatric Cardiology, General Hospital of Southern Theater Command, People’s Liberation Army, Guangzhou 510010, China; (H.C.); (N.W.); (J.H.); (R.W.); (J.C.)
- School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Guangzhou 510006, China; (W.Z.); (A.C.)
| | - Ruixin Wang
- Department of Geriatric Cardiology, General Hospital of Southern Theater Command, People’s Liberation Army, Guangzhou 510010, China; (H.C.); (N.W.); (J.H.); (R.W.); (J.C.)
| | - Jianing Chi
- Department of Geriatric Cardiology, General Hospital of Southern Theater Command, People’s Liberation Army, Guangzhou 510010, China; (H.C.); (N.W.); (J.H.); (R.W.); (J.C.)
| | - Wei Zhang
- School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Guangzhou 510006, China; (W.Z.); (A.C.)
| | - Linping Zhao
- Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China; (R.Z.); (L.Z.)
| | - Hong Cheng
- Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou 510515, China;
| | - Ali Chen
- School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Guangzhou 510006, China; (W.Z.); (A.C.)
| | - Shiying Li
- Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China; (R.Z.); (L.Z.)
| | - Lin Xu
- Department of Geriatric Cardiology, General Hospital of Southern Theater Command, People’s Liberation Army, Guangzhou 510010, China; (H.C.); (N.W.); (J.H.); (R.W.); (J.C.)
- Graduate School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China
| |
Collapse
|
2
|
Ramaswamy A, Joshi A, Noronha V, Patil V, Sahu A, Manickam DR, Kothari R, Sable N, Agrawal A, Menon S, Prabhash K. Poor Risk Advanced Renal Cell Carcinoma: Outcomes from a Registry in a Tertiary Cancer Center. Indian J Med Paediatr Oncol 2017; 38:311-315. [PMID: 29200680 PMCID: PMC5686973 DOI: 10.4103/ijmpo.ijmpo_154_16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
BACKGROUND Poor-risk advanced Renal cell carcinoma (RCC) are an under-evaluated and difficult to treat subset of patients with poor prognosis. While Temsirolimus is the approved first line therapy for this category, Tyrosine kinase inhibitors (TKIs) are also commonly uses as initial treatment. We present an analysis of poor-risk advanced RCC treated in our institute. MATERIALS AND METHODS Patients diagnosed as poor-risk (as per Heng criteria) advanced RCC from June 2008 to December 2015 were analysed for baseline demographics, treatment received, toxicity (primarily Grade 3 and Grade 4), response rates (RR) and survival. RESULTS 60 patients (43 males, 17 females) with a median age of 53 years were included for final analysis. Median ECOG PS was 1, clear cell was the predominant histology (63.3%), and 46.7% of patients had greater than 2 sites of metastases. Sorafenib, Sunitinib, Temsirolimus and Pazopanib were used to treat 43.3%, 36.7%, 8.3% and 6.7% of patients respectively, while 3 patients were offered upfront best supportive care. Common adverse events included skin rash (31.5%), HFS (Grade 2 and 3 - 30.8%), mucositis (26.3%), hypertension (24.5%), and dyslipidaemias (22.8%). 41 patients were available for response - overall response rate observed was 15%, while clinical benefit rate was 50%. Median progression free survival was 5.78 months (4.67-6.89) and median overall survival (OS) was 10.05 months (7.31-12.79). CONCLUSION A majority of poor-risk metastatic RCC patients in our study were treated with TKIs and the survival outcomes appear to suggest that this strategy is a feasible alternative to Temsirolimus in the Indian setting.
Collapse
Affiliation(s)
- Anant Ramaswamy
- Department of Medical Oncology, Radiology,Nuclear Medicine and Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India
| | - Amit Joshi
- Department of Medical Oncology, Radiology,Nuclear Medicine and Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India
| | - Vanita Noronha
- Department of Medical Oncology, Radiology,Nuclear Medicine and Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India
| | - Vijay Patil
- Department of Medical Oncology, Radiology,Nuclear Medicine and Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India
| | - Arvind Sahu
- Department of Medical Oncology, Radiology,Nuclear Medicine and Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India
| | - Deepan R Manickam
- Department of Medical Oncology, Radiology,Nuclear Medicine and Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India
| | - Rushabh Kothari
- Department of Medical Oncology, Radiology,Nuclear Medicine and Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India
| | - Nilesh Sable
- Department of Medical Oncology, Radiology,Nuclear Medicine and Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India
| | - Archi Agrawal
- Department of Medical Oncology, Radiology,Nuclear Medicine and Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India
| | - Santosh Menon
- Department of Medical Oncology, Radiology,Nuclear Medicine and Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India
| | - Kumar Prabhash
- Department of Medical Oncology, Radiology,Nuclear Medicine and Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India
| |
Collapse
|
4
|
Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget 2010; 1:530-543. [PMID: 21317449 PMCID: PMC3248125 DOI: 10.18632/oncotarget.188] [Citation(s) in RCA: 237] [Impact Index Per Article: 16.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2010] [Accepted: 10/21/2010] [Indexed: 11/25/2022] Open
Abstract
It is well established that the PI3K pathway plays a central role in various cellular processes that can contribute to the malignant phenotype. Accordingly, pharmacological inhibition of key nodes in this signaling cascade has been a focus in developmental therapeutics. To date, agents targeting upstream receptor tyrosine kinases are best studied and have achieved greatest clinical success. Further downstream, despite efficacy in certain tumor types, the rapalogs have been somewhat disappointing in the clinic. Novel inhibitors of PI3K, Akt, and mTORC1 and 2 are now passing through early phase clinical trials. It is hoped that these agents will circumvent some of the shortcomings of the rapalogs and lead to meaningful benefits for cancer patients.
Collapse
Affiliation(s)
- Ben Markman
- Centre for Cancer Research, Monash Institute of Medical Research, Southern Health, Melbourne, Victoria, Australia
| | - Rodrigo Dienstmann
- Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain
| | - Josep Tabernero
- Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain
| |
Collapse
|